CRISPR THERADRN financial statements, including revenue, expenses, profit, and loss

The total revenue of C2RS34 for the last quarter is 2.90 M BRL, and it's 14.49% higher compared to the previous quarter. The net income of Q2 24 is -708.96 M BRL.